Clinical Research Directory

Phase 1 Trial to Evaluate 150 mg Subcutaneous CIT-013

Sponsor: Citryll BV

Summary

This is a phase 1, double-blind, randomized, placebo-controlled, single center, repeat-dose trial for the assessment of safety, tolerability, bioavailability and pharmacokinetic profiles of 150 mg CIT-013 in healthy adult volunteers

Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Trial to Evaluate 150 mg Subcutaneous CIT-013 Administration in Healthy Adult Volunteers

Key Details

Conditions

Interventions

Locations (1)